firmagon
ferring pharmaceuticals a/s - degarelix - prostatiske neoplasmer - endokrine terapi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
lamotrigin "stada" 100 mg dispergible tabletter
stada arzneimittel ag - lamotrigin - dispergible tabletter - 100 mg
lamotrigin "stada" 200 mg dispergible tabletter
stada arzneimittel ag - lamotrigin - dispergible tabletter - 200 mg
lamotrigin "stada" 25 mg dispergible tabletter
stada arzneimittel ag - lamotrigin - dispergible tabletter - 25 mg
lamotrigin "stada" 50 mg dispergible tabletter
stada arzneimittel ag - lamotrigin - dispergible tabletter - 50 mg
vivelle dot 100 mikrog./24 timer depotplastre
sandoz a/s - estradiolhemihydrat - depotplastre - 100 mikrog./24 timer
vivelle dot 25 mikrog./24 timer depotplastre
sandoz a/s - estradiolhemihydrat - depotplastre - 25 mikrog./24 timer
vivelle dot 37,5 mikrog/24 timer depotplastre
sandoz a/s - estradiolhemihydrat - depotplastre - 37,5 mikrog/24 timer
vivelle dot 50 mikrog./24 timer depotplastre
sandoz a/s - estradiolhemihydrat - depotplastre - 50 mikrog./24 timer
vivelle dot 75 mikrog./24 timer depotplastre
sandoz a/s - estradiolhemihydrat - depotplastre - 75 mikrog./24 timer